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Abstract
Background: Highly pathogenic influenza viruses pose a constant threat which could lead to a global pandemic.
Vaccination remains the principal measure to reduce morbidity and mortality from such pandemics. The availability and
surging demand for pandemic vaccines needs to be addressed in the preparedness plans. This study presents an improved
high-yield manufacturing process for the inactivated influenza H5N1 vaccines using Madin-Darby canine kidney (MDCK)
cells grown in a serum-free (SF) medium microcarrier cell culture system.
Principal Finding: The current study has evaluated the performance of cell adaptation switched from serum-containing (SC)
medium to several commercial SF media. The selected SF medium was further evaluated in various bioreactor culture
systems for process scale-up evaluation. No significant difference was found in the cell growth in different sizes of
bioreactors studied. In the 7.5 L bioreactor runs, the cell concentration reached to 2.3610
6 cells/mL after 5 days. The
maximum virus titers of 1024 Hemagglutinin (HA) units/50 mL and 7.160.3610
8 pfu/mL were obtained after 3 days
infection. The concentration of HA antigen as determined by SRID was found to be 14.1 mg/mL which was higher than those
obtained from the SC medium. A mouse immunogenicity study showed that the formalin-inactivated purified SF vaccine
candidate formulated with alum adjuvant could induce protective level of virus neutralization titers similar to those
obtained from the SC medium. In addition, the H5N1 viruses produced from either SC or SF media showed the same
antigenic reactivity with the NIBRG14 standard antisera.
Conclusions: The advantages of this SF cell-based manufacturing process could reduce the animal serum contamination,
the cost and lot-to-lot variation of SC medium production. This study provides useful information to manufacturers that are
planning to use SF medium for cell-based influenza vaccine production.
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Introduction
Influenza is a highly contagious disease that affects the
respiratory system, and some severe cases could lead to
hospitalization or even death. In recent years, human infection
with highly pathogenic avian influenza H5N1 viruses has and still
poses a serious threat to public health. According to the bulletin of
the World Health Organization (WHO), there were 293 deaths
among the 496 human cases recorded in 15 countries throughout
Africa, Asia, and Europe [1]. If H5N1 viruses continue to evolve
and acquire the ability to cause widespread human-to-human
transmission, this could result in an influenza pandemic. When a
pandemic occurs, the outbreak will have significant impacts on
health systems and economies in every affected country. The
WHO believes that vaccination is the best preventive method to
reduce the chance of severe illness or death when humans are
exposed to H5N1 viruses. To prevent such pandemics,
effective influenza vaccines should be made available as early as
possible.
In the past, inactivated seasonal influenza vaccines have been
manufactured by egg-based processes; however, the current global
supply using this method is only able to cover a small percentage of
the world’s growing population. The efficiency of this manufac-
turing method is low, and it requires one to two eggs to produce
one dose of vaccine [2]. Furthermore, the surge demand of H5N1
vaccine would require the switch from the seasonal vaccine
production to pandemic vaccine manufacturing processes that
currently are the bottle-neck and inadequately addressed by the
vaccine manufacturers to meet the global vaccination program
recommended by the WHO. An alternative to the egg-based
processes is virus propagation in mammalian cell lines which has
been used for the production of influenza vaccines [3,4,5]. Cell-
derived influenza vaccines are capable of providing equivalent or
even better protection in animal models than those obtained from
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to be safe and highly efficacious in humans [2,8,9,10]. Cell-based
flu vaccines offer a number of advantages over the traditional
method: (a) cell lines are fully characterized and in compliance
with regulatory guidelines [2]; (b) the raw materials for production
are defined and can be easily produced in a short period [2,9].
There are two regulatory-approved continuous cell lines being
used for influenza vaccine production: MDCK (Madin-Darby
canine kidney) cells and Vero (African green monkey kidney) cells
[5,8,10]. These two cell lines can be cultured either in free-
suspension or in a microcarrier culture system.
Serum, used as the source of nutrients, hormones and growth
factors, is required for optimal growth of mammalian cells [11].
These serum factors also facilitate the attachment and spreading of
cells, and provide protection against mechanical damage and
shear forces [12,13]. Besides these advantages, however, serum
may contain unwanted contaminants which are a primary concern
in the safety of biological products [14]. In addition to the
potential adventitious viral contaminants and prion contamina-
tion, SC medium also has other production issues such as lot-to-lot
variability. SC medium usually contains a high percentage of
serum content (up to 10%), which increases difficulty in
downstream purification. The switch from SC medium to SF
medium in animal cell cultures has become a major trend for the
cell-based products [15,16,17,18,19]. Some influenza virus
production in MDCK cells grown on microcarriers in SF medium
have been reported in the literature [16,20]. Although the cell-
based seasonal flu vaccines are available in European markets,
there is little information available on the manufacturing processes
and the culturing systems. In addition, because of intellectual
property rights and the proprietary technologies used in these
vaccine products, the availability of comparison studies on virus
and product yield influenced by the compositions of culture
medium between SC and SF medium and systems used are very
limited.
In this study, we describe a well defined manufacturing process
for influenza H5N1 vaccine production that enables the switch
from Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 5% fetal bovine serum (FBS) to SF medium (Plus-MDCK) in
a microcarrier cell culture bioreactor system for MDCK cell
propagation. Higher virus yield was found in the selected SF
medium. In addition, the antigenicity analysis and mouse
immunogenicity study have shown that MDCK cell-based vaccine
produced in SF medium are equivalent to those produced in SC
medium. The current results also demonstrate the production
scalability from the spinner flasks to a pilot-scale microcarrier
bioreactor system.
Results
Evaluation and selection of SF medium
To avoid the long duration for MDCK cells to adapt to a new
culture media, the performance of different media in cell growth
was screened and evaluated by the direct adaption method. The
selection criteria were based on consistent cell growth performance
over a few passages. The cells were cultured in three different
commercially available SF media (Plus-MDCK, VP-SFM and
ExCell) and one SC medium (DMEM with 5% FBS supplement)
in 75 cm
2 flasks over three passages after inoculation. The initial
seeding cell number was 1.0610
6 cells/per flask. In all
experiments, the final glucose concentration was maintained
adequately to avoid the depletion of nutrients. Indicators such as
total cell number, viability, and morphology were monitored over
the testing period. The total cell numbers obtained from different
media were calculated based on the cells cultured in the T-flask
with DMEM+5% FBS (SC) medium reaching 90% confluency on
day 3. The samples in each culture media were performed in
triplicate. The definition of cell fold-increase is defined and
calculated based on the final total cell number divided by the
initial cell number. Figure 1 illustrates the increase of MDCK cell
growth in different culture media with 3 consecutive passages. As
shown in figure 1, the cell counts in the SC medium were found to
be higher than those found in the SF media (p,0.01). This could
be due to serum provided containing more growth factors for
MDCK cells to grow. In contrast, the SF media might not have
sufficient growth factors like the SC medium for supporting cell
growth. Without further culture medium adaption, VP-SFM and
ExCell media showed high fluctuations and lower cell growth
rates. The culture in Plus-MDCK medium with three passages
showed similar levels in cell growth profile. It appears that the
Plus-MDCK SF medium could consistently promote cell growth
and meet the medium selection criteria. Thus, the Plus-MDCK SF
medium was selected and used in all later experiments.
Serum-free medium cultivations in various sizes of
microcarrier bioreactor systems
To evaluate the influences of culture-vessel size on cell growth in
the Plus-MDCK medium, MDCK cells were cultured in three
different-sized bioreactors with a fixed amount (5 g/L) of Cytodex
1 microcarriers. Figure 2 shows the MDCK cell growth profiles
in 125 mL spinner flask, the 2.2 L and 7.5 L bioreactors. Shortly
after inoculation, the cells had attached to the microcarriers and
started to colonize the surface. The cell density in three different
bioreactors decreased slightly at the beginning and then increased
steadily after inoculation. After 5 days inoculation, the cells on
microcarriers were .90% confluent. Cell densities increased more
than 10-fold from an initial concentration of 2.0610
5 cells/mL to
2.3610
6 cells/mL. During the cultivation of the cells grown in
various sizes of bioreactors, no significant difference in cell density
was observed.
Production of viral antigens
The MDCK cells in the 125 mL spinner flask, the 2.2 L and
7.5 L bioreactors were infected with NIBRG14 viruses using a
very low multiplicity of infection (MOI). Due to viral infection, the
cytopathic effect (CPE) was observed in the MDCK cells grown on
the microcarriers. It is worth pointing out that the concentrations
of glucose and other substrates depleted readily after 48 hrs
infection (data not shown) which was before the viral infection
media exchange was performed to avoid the nutrient limitation.
Virus titers (HA and plaque assay) are evaluated and shown in
Table 1. The virus yield and HA titers were found to be 1024 HA
titer/50 mL and .5610
8 pfu/mL and no significant differences
between the various vessel sizes used (125 mL spinner flask, the
2.2 L and 7.5 L bioreactors). Therefore, all further experiments
were performed with 7.5 L bioreactor.
Similar to the spinner flask results, MDCK cell density grown in
the 7.5 L bioreactor was found to be higher in the SC medium
(.6610
6 cell/mL) than those obtained from the SF medium
(2.3610
6 cell/mL). But the virus yield and HA titers at the 3
rd day
harvest had very similar values (1024 HA titer/50 mL and
.7610
8 pfu/mL) obtained from the SC study. Samples taken
from the 7.5 L bioreactor during the infection period were further
analyzed for HA antigen concentration, and then compared with
the values obtained from the SC study. The HA antigen
concentrations were determined by the single-radial immunediffu-
sion (SRID) assay [21] and shown in Figure 3. The HA
concentrations increased with infection time. The concentrations
Influenza H5N1 Vaccines
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e14578of HA antigen in day 1 were under the detection limit. On the
harvest day, the HA antigen concentration from the SF culture
was found to be 14.1 mg/mL on average over three runs, whereas
the average 12.7 mg of HA antigen/mL was found in the SC
culture. It shows that the titer of HA antigen produced from SF
medium was slightly higher than that from SC medium (p,0.05).
Influenza H5N1 virus produced in the SF medium was further
concentrated, sucrose-gradient purified, and formalin-inactivated
Figure 2. The growth of MDCK cells on microcarrier in each cultured system. MDCK cells were grown either in the 125 mL spinner flask, or
2.2 L or 7.5 L bioreactors with 5 g/L of Cytodex 1 microcarriers. Cell densities were measured on each day and found to increase more than 10-fold
from an initial concentration of 2.0610
5 cells/ml to confluency at 2.3610
6 cells/ml after 5 days. The cell growth in various bioreactors did not show
any significant difference of cell density based on the student t-test.
doi:10.1371/journal.pone.0014578.g002
Figure 1. Comparison of MDCK cell growth in different culture medium. Three commercially available serum-free media (Plus-MDCK, VP-
SFM, and ExCell) and one SC medium (DMEM+5% FBS) were used to evaluate the suitability for MDCK cells directly grown in 75 cm
2 T-flasks. The
thawed MDCK cells were directly cultured in four different media over 3 passages. The cell numbers were determined based on the harvest when the
cell grown in SC had reached 90% confluency in day 3. The cell count in each medium was performed in triplicate. The increase of cell growth
(number of fold increase) is calculated based on the final total cell number divided by the initial cell number.
doi:10.1371/journal.pone.0014578.g001
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amount of HA found in the harvest, the average of the total
recovery rate of HA yield was around 45%. In the antigenicity
study, the experiments were performed on the H5N1 viruses
produced from different culture (SC and SF) media and found to
have the same reactive titer (400) with the NIBRG14 standard
antibody obtained from the WHO reference laboratory. These
titers show that high-yield MDCK cell-based influenza vaccine
production is possible using the current SF bioreactor technology.
Mouse immunogenicity study
The purified H5N1 viruses were purified by sucrose gradient
zonal centrifugation and then pooled from high HA-titer fractions;
thus the purified samples contained only small amounts of
impurities as analyzed by the Western blot using antisera raised
against MDCK cell lysate (data not shown). To perform mouse
immunogenicity, different amounts of the formalin-inactivated
H5N1 vaccine candidate produced in the SF medium were
formulated with alum adjuvant and then injected into different
groups of mice to test their ability to induce immune responses. All
mice were immunized with two doses. Results obtained from the
control group (PBS in Group 1) and the two different doses of
H5N1 flu vaccine candidates (0.2 and 1 mg of HA/dose in Groups
2 and 3, respectively) were summarized in Table 2. The GMT of
HI titers generated from mice immunized with low dosage (0.2 mg
of HA, Group 2) and high dosage (1 mg of HA, Group3) were
found to be 80 and 285, respectively. These results indicate that
the H5N1 vaccine antigens could induce dosage-dependent
antibody responses after two injections. In addition, 100% of
seroprotection rates (40 HI titer is considered as the level of
seroprotection by CHMP criteria) were observed in both Groups 2
and 3 after two doses of immunization. The data presented in
Table 2 demonstrated that 100% protection could be achieved
with as little as 0.2 mg of HA antigen in the mouse model. A
similar finding was reported by a previous study [10]. The current
results show that the cell-based H5N1 viral antigens produced
from SF medium could induce strong and efficacious immune
responses similar to those obtained from the H5N1 virus produced
from the SC medium reported in our previous study [4].
Discussion
The pandemic potential of the highly pathogenic avian
influenza H5N1 virus highlights the urgent need for an effective
vaccine. We and others are searching for a robust and well-
controlled vaccine manufacturing system that is capable of
producing large amounts of vaccine antigens within a short period
of time. Traditional technologies using embryonated eggs to
produce the split vaccines may not fulfill all these criteria [10].
More importantly, the cell-based process is completely indepen-
dent of the supply of eggs that may be endangered during a
pandemic. The use of cell culture as an alternative approach for
influenza virus production has gained significant interest in recent
years. Several cell lines, such as MRC-5, WI-38, FRhL, Vero and
MDCK, have been assessed for their ability as the production
Table 1. Production of virus titers in various microcarrier/
bioreactor systems.
HA titer*
(HA units/50 ml)
plaque assay
(pfu/ml)
Spinner flask 1024 4.860.3610
8
2.2 L bioreactor 1024 7.660.5610
8
7.5 L bioreactor 1024 7.160.3610
8
*The HA titer were performed in triplicate in 96-well microplates using turkey
red blood cells according to the standard technique [29].
doi:10.1371/journal.pone.0014578.t001
Figure 3. Production of HA antigens produced either in SC or SF medium. Samples taken from the 7.5 L bioreactor during the infection
period were analyzed for HA antigen content. The harvest of HA antigen reached a peak at 14.1 mg/mL on day 3 post infection, as determined by
SRID assay. By contrast, the harvest from the SC medium was 12.7 mg of HA/mL.
doi:10.1371/journal.pone.0014578.g003
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available cell-based influenza vaccines are commonly produced
from either Vero or MDCK cells. In 2002, a vaccine from Baxter
received approval for InflujectH, which is a formalin-inactivated
whole-virion influenza vaccine produced in Vero cells grown in SF
Medium. In 2007, Novartis received approval for its product
Optaflu, a trivalent MDCK cell-derived seasonal influenza vaccine
produced in SF medium. Optaflu was the first commercially
inactivated flu vaccine derived from MDCK cell cultures. It is
important that cell-based influenza vaccine manufacturing pro-
cesses using the selected cell lines can produce high virus yield and
HA titers from a wide variety of influenza virus strains. Recent
studies have already shown that MDCK cells are the most suitable
substrate for prorogating influenza virus [2,4,7,16,20,22]. MDCK
cells not only enable the growth of different influenza virus strains
but also produce good virus yield with relatively high HA titers
[23]. As most vaccine manufactures have kept secret about their
technical know-how and proprietary manufacturing processes,
little information is known about how the commercial vaccines
were made. Thus, it is not easy to make appropriate comparisons
on each process step and to analyze how different medium
formulations could influence the cell growth and virus yield. We
describe here the advantages of an inactivated whole virus H5N1
vaccine manufacturing process using MDCK-cell based cell
culture system in SF medium.
Over the past decades, serum was used as the essential
component of cell-culture media for facilitating cell growth.
However, the use of serum presents several disadvantages such as
potential to induce hypersensitivity [24], batch variability,
possibility of introducing contaminants such as bovine viruses,
prions, mycoplamas, etc. Therefore, process development for
biopharmaceutical products under conditions which are free of
animal components reduces the contamination risk and the
difficulty in removing the impurities from the downstream
purification steps [17]. As a result, these products will be of high
quality and consistently safe [25]. In recent years, much attention
has focused on the use of SF medium instead of SC medium in
cell-based vaccine and biologics production. It is a demanding task
to develop a viable process using SF medium formulation for both
cell growth and virus replication. Currently, there is no validated
analytical method for monitoring cell or virus growth. Empirical
experiments appear to be a reliable approach used to determine
the optimal condition for both cell growth and virus replication
stages. Several commercially available media such as VP-SFM
from Invitrogen; ExCell MDCK from JRH; Plus MDCK from
Cesco Bioengineering are designed for MDCK cell cultures. The
current study was performed to identify a high virus-yield SF
medium as a possible replacement for the SC process reported in
our previous study [4]. Three commercially available SF media
listed above were assessed for their ability promoting MDCK cell
growth and compared with those obtained from a SC medium. In
the SF medium screening experiments, the direct adaptation
method for cell growth is considered to be the easiest way to
minimize adaptation time switching from SC medium to SF
medium. This approach can reduce the concerns of cell physiology
changes due to long sub-cultured adaption. The T-flasks was used
to assess whether these SF medium could support MDCK cell
growth in a static environment. Cells sub-cultivated over three
passages in Plus-MDCK showed a consistent performance. This is
the key criteria to evaluate the feasibility of using this SF medium
for further process development. Other SF media such as VP-SFM
and ExCell did not support MDCK cell growth well in our direct
cell adaption approach. It indicates that these two SF media are
not yet optimized for MDCK cells. A similar observation was also
reported by Genzel et. al. [20] that ExCell medium did not
support MDCK cell growth. Although Plus-MDCK medium was
shown to be a good candidate for the production of influenza
H5N1 vaccines, very limited information is known about the key
factors in this SF medium formulation. Thus, it is hard to evaluate
how these components influence cell density and virus yield.
When cells are grown in dynamic environments such as that of
bioreactor cultivation, the viability of growth of cells can be
strongly affected by shear in the environment [12]. This is always a
challenge to design a robust system that can support cells growing
in SF medium. Cultures in serum-supplemented media protect
cells against the detrimental effect of sparging [13]. This situation
could be worse if cells are cultured in SF medium. The addition of
shear protectant such as Pluronic F-68 in SF medium is often
needed to protect cells from damage by shear forces [26]. The
solution to this method is to use bubble-free aeration by using
silicone tubing [27]. Batch bioreactor cultures of MDCK cells in
SF medium have been reported by others [3,20,28]. The virus
titers among these studies were not very high (,10
6 pfu/mL). In
the current study, a bubble-free bioreactor culture of MDCK cells
in Plus-MDCK medium with 5 g/L of microcarriers using
perfusion mode, resulted in a higher virus titer level (,10
8 pfu/
mL as shown in Table 1). Without a long cell adaptation in
medium exchange procedure, the current results confirm that a
fast and user-friendly SF medium manufacturing process has been
developed and the culture conditions are established for scale-up.
A comparison of HA protein antigen produced in the SF
medium to the results from the SC medium was performed.
Interestingly, the cell density was lower in SF medium, but the
yield of H5N1 antigen was found to be slightly higher based on the
SRID assay (Figures 1 & 3). This observation was never reported
in the literature. This phenomenon is unclear and not well
understood. It could be the components of residual serum acting as
anti-protease to neutralizing and stopping the host trypsin-like
protease cleavage of HA antigens that is normally required for flu
virus replication. Another explanation could be the different
composition between SF and SC medium resulted in different
cellular metabolism or apoptosis that could influence the virus
replication and virus yield.
In summary, the current study has demonstrated that: (i) SF
medium (Plus MDCK) could support both the cell-growth in the
solid microcarriers and H5N1 virus-replication in the well
controlled and scalable bioreactors; (ii) the cell-based flu vaccines
could be manufactured in a safe and user-friendly process with
fewer contaminants and consistently high yield. The use of SF
medium certainly could help to reduce the concerns of the bovine
Table 2. Immunogenicity of inactivated influenza H5N1
vaccine candidates in mice.
Group 1 Group2 Group 3
HA (mg/dose)
AlPO4 (mg of Al/dose)
Number of animals
0
300
6
0.2
300
6
1.0
300
6
HI GMT (95% CI)
Prevaccination
Post-dose1
Post-dose2
,10
,10
,10
,10
40 (14–112)
80 (50–127)
,10
32 (18–57)
285 (139–583)
HI seroprotection
Prevaccination
Post-dose1
Post-dose2
0%
0%
0%
0%
67% (4/6)
100% (6/6)
0%
50% (3/6)
100% (6/6)
doi:10.1371/journal.pone.0014578.t002
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simplifying raw-material sources analysis. Plus-MDCK medium
not only supported MDCK cells directly, which adapted to grow
well in both T-flasks and bioreactors, but also enhanced the virus-
replication and generated high infectious virus titers (,10
8 pfu/
mL) after 72 h following infection. In terms of material cost, we
found Plus-MDCK medium to be 55% less expensive than SC
medium. This work further illustrates that the microcarrier system
using Plus-MDCK medium poses an alternative approach for the
production of influenza H5N1 viruses at high yields. Current
preliminary studies at the 30-L scale using this approach have
been very successful (data not shown). Further work will be
extended to perform studies with the pilot-scale 150 L bioreactor
as well as other single-use culture systems.
Materials and Methods
Ethics Statement
All experiments were conducted in accordance with the
guidelines of Laboratory Animal Center of NHRI. The animal
use protocols have been reviewed and approved by the NHRI
Institutional Animal Care and Use Committee (Approved protocol
no. NHRI-095054-A).
Virus and cells
The origin of the NIBRG-14 (derived from A/Vietnam/1194/
2004) vaccine strain and MDCK cells are described in our
previous study [4]. The viruses were further amplified to generate
virus stocks in MDCK cells. MDCK cells were grown in SF
medium (Plus-MDCK). Master and working cell banks cultured
were prepared using SC medium, and then further characterized
to fulfill the cGMP guidelines for manufacturing biological
products.
Medium selection in 75 cm
2 T-flasks
Three commercially available SF media (Plus-MDCK, VP-
SFM and ExCell) and one SC medium were used in the medium
selection study. The SC medium contained basal medium DMEM
(Invitrogen, UK) and 5% fetal bovine serum (FBS). The FBS was
purchased from Moregate Biotech (Australia). Plus-MDCK
medium was purchased from Cesco Bioengineering Co., Taiwan.
VP-SFM (cat. no. 11681) was supplied by Invitrogen (UK). VP-
SFM and ExCell (cat. no. 14581C) was supplemented with 4 mM
L-glutamine before use. Each 75 cm
2 T-flask was inoculated with
approximately 1.0610
6 cells and grown for 3 days in 20 mL
medium. Each culture medium was performed in triplicate. When
cell numbers in the T-flask with DMEM+5% FBS medium
reached 90% confluency (approximately three days after inocu-
lation), the cells in each T-flask were detached by Trypsin-EDTA
(Invitrogen, UK) for cell counting. After counting cells, the same
seeding cell number of 1.0610
6 cells was sub-cultured to new
flasks. The procedure was repeated in triplicate.
Cell growth in spinner flasks
Cell culture was carried out in 125 mL spinner flasks (Corning,
USA) containing 100 mL of culture medium at 37uC in a 5% CO2
incubator. Cells were cultivated in Plus MDCK. The stirring speed
was maintained at 45 rpm. The spinner flasks were inoculated with
2610
5 cells/mL. The experiments were carried out in duplicate.
Samples were taken daily to perform various off-line analyses.
Bioreactor cultures
The cultures were performed in 2.2 L and 7.5 L bioreactors
(NBS, USA) with working volumes of 1.4 L and 5 L, respectively.
Cytodex 1 microcarriers (GE Healthcare, USA) were hydrated,
autoclaved, and preconditioned according to the manufacturer’s
instructions before use. The seeding density was with 2.0610
5
cells/mL; and an agitation speed was maintained at 35–50 rpm.
During cell growth, pH, dissolved oxygen and temperature were
maintained at 7, 50% air-saturation, and 37uC, respectively.
Perfusion rate was adjusted daily to maintain glucose concentra-
tion at around 1 g/L. When the cells on the microcarrier were
fully confluent, the medium was exchanged with 90% of fresh
medium. 2 mm/mL of TPCK-trypsin was added to the medium
before viral replication (Invitrogen, USA), and the cells were
infected with a multiplicity of infection (MOI) of 0.00001. Samples
were taken daily to determine cell density and viral assays. Each
bioreactor culture was repeated twice.
Virus titration
HA titration was conducted in 96-well microplates using turkey
red blood cells (RBC) according to the standard technique [29].
Virus infectious titers were measured using plaque assay based on
plaque forming units (pfu) in MDCK cells [29]. A positive control
with pre-specified acceptable ranges of titers was included for
conducting HA and plaque assays.
Purification of vaccine antigens
The SF-produced H5N1 virus was purified according to the
procedure described in the previous study [4]. Vaccine antigens
produced from the 7.5 L bioreactor were harvested through a
0.65 mm depth filter; and the clarified solution was then
concentrated by an ultrafiltration step using 300K membrane
(Sartorius, Germany). The concentrated samples were purified
using the sucrose-density gradient zonal centrifugation (CP-80,
Hitachi, Japan). The fractions containing the purified whole virus
particles were pooled together. A diafiltration step was used to
remove sucrose content. The purified viruses were inactivated with
0.01% of formalin. Virus inactivation was confirmed by plaque
assays. The HA antigen protein concentrations were measured
using SRID assay [21]. The purified HA antigen of the SC culture
from the previous study [4] was stored at 280uC and was taken for
comparison study. The analysis of HA antigen was repeated three
times. The standard HA antigen and antiserum were purchased
from the HPA, UK.
Antigenicity Analysis
Antigenicity analysis of the influenza viruses (NIBRG14) was
carried out by HI assay using the standard anti-H5N1 antibody
that was purchased from the National Institute for Biological
Standards and Control (NIBSC code: 04/214). The MDCK cells
were cultivated in the SC medium (DMEM+5% FBS) or the SF
medium (Plus-MDCK). The same operating procedure was
followed by the earlier section of cell growth in spinner flasks.
The samples were taken on day 3 from 125-mL spinner flask
cultures using the SC medium or the SF medium. The HI assay
started at a serum dilution of 1:100. Each sample was performed in
triplicate.
Mouse immunogenicity study
Six- to eight-week-old female BALB/c mice were immunized
intramuscularly with two doses of vaccine antigen at a 2-week
interval. Three groups with the same amount of adjuvant but
containing different HA dosages were compared. These groups
were 300 mg AlPO4, 0.2 mgo fH A +300 mg AlPO4, and 1.0 mgo f
HA+300 mg AlPO4. Sera were collected on day 0, day 14, and day
21 for measuring HI titers. The animal study was approved by the
Influenza H5N1 Vaccines
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protocol no. NHRI-095054-A).
Serological assays
Serum HI antibody titers were measured using turkey red blood
cells and HA units of virus antigens following WHO’s standard
procedures [29]. Serum neutralizing antibody titers were deter-
mined using MDCK cells and are expressed as the reciprocal of
the highest dilution of serum that gave 50% neutralization of 100
TCID50 of the vaccine virus following the WHO standard
procedures [29]. Sera giving a negative signal in the first dilution
(,1:10) were assigned a nominal HI score of 1:5. HI titers are
expressed as the reciprocal of serum dilution. Animal cells with a
serum HI titer of $40 were considered seroprotected according to
the European Union Committee for Medicinal Products for
Human Use (CHMP) criteria. The definition of serocoversion
followed CHMP criteria (4-fold increase from the baseline).
Seroconversion, seroprotection, geometric mean titers (GMT),
and their respective 95% confidence intervals (95% CI) were
applied for analyzing antibody titers.
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